Novel biomarkers for human cervical cancer and/or HPV infection

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention identifies a group of novel genetic biomarkers that can be used to diagnose human cervical cancer and persistent HPV infection. The biomarkers allow for more accurate detection, monitoring, and staging of cervical cancer using samples such as biopsies, blood, or cervical smears. Diagnostic kits and methods built around these biomarkers, including gene expression or protein analysis, offer improved early detection and patient-specific management. The invention also proposes new therapeutic strategies using drugs that target pathways highlighted by these biomarkers, such as darapladib and angiocidin.

Use CasesContent extracted from patent full text and abstract with AI.

• Early and accurate diagnosis of cervical cancer in patients, especially those infected with HPV.
• Determining the stage of cervical cancer to enable more precise clinical management.
• Screening for persistent HPV infections that have a high risk of progressing to cancer.
• Personalized monitoring of treatment effectiveness by tracking biomarker levels over time.
• Identifying high-risk patient groups for more aggressive intervention or preventative therapy.
• Development and provision of diagnostic kits for use in clinical laboratories or point-of-care settings.
• Drug discovery and screening for new anti-cervical cancer or anti-HPV agents targeting identified biomarkers.
• Developing patient-tailored therapies based on individual biomarker profiles.

BenefitsContent extracted from patent full text and abstract with AI.

• Allows for early and accurate detection of cervical cancer, potentially improving patient outcomes.
• Enables more precise staging of cancer, guiding tailored therapeutic decisions.
• Provides objective, reproducible biomarkers rather than relying on subjective histopathological analysis.
• Improves ability to monitor disease progression and treatment response non-invasively.
• Supports the development of new diagnostic kits that are easier and potentially faster to use.
• Facilitates personalized treatment approaches, reducing unnecessary therapy and focusing on likely responders.
• Enables identification and development of novel drugs based on biomarker pathways, potentially leading to more effective or targeted treatments.
• Reduces the risk of misdiagnosis and can help distinguish between benign HPV infections and those likely to progress to cancer.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to diagnostic biomarkers for human cervical cancer and/or HPV infection. These biomarkers help to make clinical decisions that result in improvements in the diagnosis and therapy of cervical cancer, in particular in staging thereof, and thus an early diagnosis of said cancer. Further aspects relate to diagnostic kits comprising said biomarkers, and uses thereof.